<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566655</url>
  </required_header>
  <id_info>
    <org_study_id>CSM/OP/2011</org_study_id>
    <secondary_id>2012-005814-20</secondary_id>
    <nct_id>NCT02566655</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis</brief_title>
  <acronym>CSM/OP/2011</acronym>
  <official_title>Phase I Clinical Trial To Evaluate The Intravenous Infusion Of Autologous Fucosylated Bone Marrow Mesenchymal Cells Therapy In Patients With Established Osteoporosis and Low Impact Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Red de Terapia Celular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish National Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health Service, Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BIONAND, Universidad de Málaga, IBIMA, Ciber-bbn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo de Tecnología Sanitaria CIBER-BBN, Inst. Biomecánica de Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Red de Terapia Celular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of intravenous infusion of fucosylated
      autologous bone marrow cells as a new therapy in patients with established osteoporosis by a
      prospective, single-center, open, non-randomized and unblinded clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of serious and non-serious adverse events related to the procedure.</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>During time frame the following items will be considered:
Adverse effects related to the infusion moment. Occurrence of infectious complications after infusion of mesenchymal stem cells, because of the immunosuppressive effect of these cells.
Appearance of procedure-related neoplasias.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of new fractures</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, measured by Visual Analog Scale</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>To measure pain, visual analogue scale (VAS) was used where 0 is no pain and 10 the worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality, measured by Oswestry Disability Questionnaire</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>To identify the functional repercussion of lumbar pain, Oswestry Disability Questionnaire for back pain or Oswestry Disability Index is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, measured by EuroQoL-5D test</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>To measure the quality of life EuroQoL-5D psychometric test is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone resorption, measured by biochemical index</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Aminoterminal telopeptide of type 1 collagen in the serum (serum NTX) (%) by ELISA technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone formation, measured by biochemical index</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Osteocalcin in the serum by ELISA (BPG serum) (ng / mL) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone formation, measured by biochemical index</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Bone specific alkaline phosphatase in the serum by ELISA (serum FAO) (ug / L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone formation, measured by biochemical index</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Aminoterminal propeptide of procollagen type 1 in the serum by ELISA (serum P1NP) (ng / mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone metabolism, measured by biochemical index</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Osteoprotegerin (OPG) (pmol / L) in the serum by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone metabolism, measured by biochemical index</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Ligand receptor activator of nuclear factor KB (RANKL) (pmol / L) in the serum by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density , measured by dual energy x-ray absorptiometry (DXA)</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone structure, measured by histomorphometric evaluation</measure>
    <time_frame>baseline and 4 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular bone density measured by quantitative computed tomography of the radius</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Spinal Fractures</condition>
  <arm_group>
    <arm_group_label>Fucosylated MSC for Osteoporosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Bone Marrow fucosylated mesenchymal stem cells will be infused intravenously on Day 0. The first four patients enrolled will receive a single dose of 2 million cells/Kg and the last six patients enrolled, will receive a single dose of 5 million cells/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fucosylated MSC for Osteoporosis</intervention_name>
    <description>Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).
Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access.</description>
    <arm_group_label>Fucosylated MSC for Osteoporosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with established osteoporosis according to standard clinical criteria.

          -  Patients who give their written informed consent to participate in the study consent.

          -  Meet all the inclusion criteria

        Exclusion Criteria:

          -  Patients with concomitant systemic disease in the opinion of the investigator.

          -  Patients with rheumatoid arthritis, ankylosing spondylitis, chronic polyarticular
             arthritis.

          -  Current patients with neoplasm or history of any malignancy in the last 10 years
             except basal carcinoma or epidermoid skin.

          -  Patients with genetic disorders that are associated with secondary osteoporosis:
             Hemochromatosis, hypophosphatasia, osteogenesis imperfecta, Ehlers-Danlos syndrome,
             Marfan syndrome, Riley Day, porphyria, storage diseases syndrome.

          -  Patients receiving immunosuppressive chemotherapy or that could interfere with the
             process of cell proliferation.

          -  Transplant patients: bone marrow, kidney, liver, heart, lung.

          -  Patients with clinical criteria and anesthetics that contraindicate well sedation or
             bone marrow extraction.

          -  Patients participating in a clinical trial in the last 6 months.

          -  Patients with positive serology for hepatitis B, hepatitis C or HIV.

          -  Patients with inability to understand informed consent.

          -  Patients who are pregnant or breast-feeding actively.

          -  Patients physically fertile, defined as all women physiologically capable of becoming
             pregnant, UNLESS they are using reliable methods of contraception.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis F Linares Ferrando, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalia García Iniesta</last_name>
    <phone>+34968381221</phone>
    <email>nagarini@yahoo.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia García Iniesta</last_name>
      <phone>+34968381221</phone>
      <email>nagarini@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Luis F Linares Ferrando, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Marras Fernández-Cid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José M Moraleda Jiménez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Blanquer Blanquer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana M García Hernández, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joaquín A Gómez Espuch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentín Cabañas Perianes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Dolores López Lucas, Graduate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darío Sánchez Salinas, Graduate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisca Iniesta Martínez, Graduate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Algueró Martín, Graduate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ernesto Doménech Abellán, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mª Dolores Morales Cano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nuria Lozano Rivas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Rodriguez Valiente, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariano Espinosa de Rueda Ruiz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Becerra Ratia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bartolomé García García, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Sackstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Luis Peris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pilar María Arrabal García, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Spinal Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

